Sensus Healthcare, Inc. (NASDAQ:SRTS) CEO Joseph C. Sardano sold 9,625 shares of the business’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $6.00, for a total transaction of $57,750.00. Following the completion of the transaction, the chief executive officer now owns 1,625,821 shares of the company’s stock, valued at $9,754,926. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Sensus Healthcare, Inc. (NASDAQ:SRTS) opened at 5.98 on Wednesday. The firm has a 50-day moving average of $4.53 and a 200-day moving average of $4.32. The company’s market capitalization is $80.66 million. Sensus Healthcare, Inc. has a one year low of $3.38 and a one year high of $6.50.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.08. Sensus Healthcare had a negative return on equity of 16.40% and a negative net margin of 13.31%. The firm had revenue of $4.97 million for the quarter, compared to analysts’ expectations of $4.50 million. On average, analysts anticipate that Sensus Healthcare, Inc. will post ($0.33) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at

An institutional investor recently bought a new position in Sensus Healthcare stock. B. Riley Financial Inc. acquired a new stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) during the second quarter, according to its most recent disclosure with the SEC. The firm acquired 104,794 shares of the company’s stock, valued at approximately $421,000. B. Riley Financial Inc. owned approximately 0.77% of Sensus Healthcare as of its most recent filing with the SEC. 9.68% of the stock is currently owned by institutional investors and hedge funds.

SRTS has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Maxim Group initiated coverage on shares of Sensus Healthcare in a report on Tuesday, June 6th. They issued a “buy” rating and a $6.50 target price for the company.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy.

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Stock Ratings for Sensus Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare Inc. and related stocks with our FREE daily email newsletter.